FULGENT GENETICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
FULGENT GENETICS, INC. (FLGT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$7.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-27
- FULGENT GENETICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$7.36M.
- FULGENT GENETICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$6.71M.
- FULGENT GENETICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$20.32M, a 9173.66% decline from fiscal 2022.
- FULGENT GENETICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $224.00K, a 66.52% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$7.36M 10-K · filed 2026-02-27 |
| 2024-12-31 | -$6.71M 10-K · filed 2026-02-27 |
| 2023-12-31 | -$20.32M 10-K · filed 2026-02-27 |
| 2022-12-31 | $224.00K 10-K · filed 2025-02-28 |
| 2021-12-31 | $669.00K 10-K · filed 2024-02-28 |
| 2020-12-31 | $1.51M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$529.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | -$1.33M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |